SCHEMBL6820993

SCHEMBL6820993

COCCOc1c(C2=NCCN2)cc2cc(-c3ccc(Cl)cc3)ccc2c1Cl

nearest known ligand 0.43

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.42
RECQL P46063 1/20 0.42
NISCH Q9Y2I1 4/20 0.40
PDCD1LG2 Q9BQ51 5/20 0.38
CD274 Q9NZQ7 5/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6820859 0.93 NISCH (0.42) NISCHPDCD1LG2CD274
SCHEMBL6824124 0.89 NISCH (0.45) NISCHPDCD1LG2CD274
SCHEMBL6826510 0.88 NISCH (0.52) NISCHPDCD1LG2CD274
SCHEMBL6824657 0.88 NISCH (0.36) NISCHPDCD1LG2CD274
SCHEMBL6826683 0.85 NISCH (0.36) NISCHPDCD1LG2CD274
SCHEMBL6825218 0.85 KCNH2 (0.43) NISCHPDCD1LG2CD274
Hydrochloric Acid SCHEMBL7738758 0.84 KCNH2 (0.43) NISCHPDCD1LG2CD274
Hydrochloric Acid SCHEMBL7735645 0.82 LMNA (0.45) LMNARECQLNISCHPDCD1LG2CD274
Hydrochloric Acid SCHEMBL7735647 0.81 NISCH (0.50) LMNARECQLNISCHPDCD1LG2CD274
SCHEMBL4255962 0.81 NISCH (0.52) LMNARECQLNISCHPDCD1LG2CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US claimed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP claimed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP claimed
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US disclosed
WO-1999032482-A1 HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS ELI LILLY AND COMPANY (US) 1999-07-01 WO disclosed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R LMNA 3624/4885RECQL 1979/4885NISCH 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.